Mumbai, March 16
Hikal Ltd has received the Certificate of Suitability (CoS) in Europe for Ondansetron Hydrochloride Dihydrate, used to prevent vomiting during surgery and in cancer-related treatments such as chemotherapy and radiotherapy. The European Directorate for the Quality of Medicines has certified the product after evaluating its dossiers, the company said in a statement. "We have filled 3 more products for CoS in Europe apart from Ondansetron. This certificate will enable us commercialise our product for European countries", said Mr Jai Hiremath, Vice-Chairman and Managing Director, Hikal Ltd.